Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?
详细信息    查看全文
  • 作者：Lara E. Sucheston-Campbell (1)
    Alyssa Clay (1)
    Philip L. McCarthy (2)
    Qianqian Zhu (3)
    Leah Preus (1)
    Marcelo Pasquini (4)
    Kenan Onel (5)
    Theresa Hahn (2)

    1. Department of Cancer Prevention and Control     ; Roswell Park Cancer Institute ; Elm and Carlton Streets ; Buffalo ; NY ; 14263 ; USA
    2. Department of Medicine     ; Roswell Park Cancer Institute ; Elm and Carlton Streets ; Buffalo ; NY ; 14263 ; USA
    3. Department of Biostatistics     ; SUNY-Buffalo ; Buffalo ; NY ; USA
    4. Center for International Blood and Marrow Transplant Research     ; Medical College of Wisconsin ; Milwaukee ; WI ; USA
    5. Department of Pediatrics     ; The University of Chicago ; Chicago ; IL ; USA
  • 关键词：Hematopoietic cell transplantation (HCT) ; HLA typing ; Infection prophylaxis ; Non ; HLA biologic predictors ; SNPs
  • 刊名：Current Hematologic Malignancy Reports
  • 出版年：2015
  • 出版时间：March 2015
  • 年：2015
  • 卷：10
  • 期：1
  • 页码：45-58
  • 全文大小：454 KB
  • 参考文献：1. Spellman, S, Setterholm, M, Maiers, M, Noreen, H, Oudshoorn, M, Fernandez-Vina, M (2008) Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 14: pp. 37-44
    2. Hahn, T, McCarthy, PL, Hassebroek, A, Bredeson, C, Gajewski, JL, Hale, GA (2013) Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol Off J Am Soc Clin Oncol 31: pp. 2437-2449
    3. Majhail NS, Chitphakdithai P, Logan B, King R, Devine S, Rossmann SN et al. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2014.10.001 .
    4. Lee, SJ, Klein, J, Haagenson, M, Baxter-Lowe, LA, Confer, DL, Eapen, M (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110: pp. 4576-4583
    5. Boyle, AP, Hong, EL, Hariharan, M, Cheng, Y, Schaub, MA, Kasowski, M (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22: pp. 1790-1797
    6. Schaub, MA, Boyle, AP, Kundaje, A, Batzoglou, S, Snyder, M (2012) Linking disease associations with regulatory information in the human genome. Genome Res 22: pp. 1748-1759
    7. Loiseau, P, Busson, M, Balere, ML, Dormoy, A, Bignon, JD, Gagne, K (2007) HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, 鈭払, 鈭扖, 鈭扗RB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 13: pp. 965-974
    8. Gagne, K, Busson, M, Balere-Appert, ML, Absi, L, Jollet, I, Bignon, JD (2007) Relevance of KIR gene matching in unrelated hematopoietic stem cell transplantations. Tissue Antigens 69: pp. 118-122
    9. Bignon, JD, Gagne, K (2005) KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 17: pp. 553-559
    10. Yee, SW, Mefford, JA, Singh, N, Percival, ME, Stecula, A, Yang, K (2013) Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet 58: pp. 353-361
    11. Koh, Y, Kim, I, Shin, DY, Bae, JY, Kim, HK, Yoon, SS (2012) Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18: pp. 37-43
    12. Khoury, MJ, Gwinn, M, Yoon, PW, Dowling, N, Moore, CA, Bradley, L (2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?. Genet Med Off J Am Coll Med Genet 9: pp. 665-674
    13. Vora, S, Ellis, N, Onel, K (2009) Translating genetic questions into clinical answers in acute myeloid leukemia. Leuk Res 33: pp. 1448-1449
    14. Relling, MV, Ramsey, LB (2013) Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program 2013: pp. 126-130
    15. Hansen, JA, Chien, JW, Warren, EH, Zhao, LP, Martin, PJ (2010) Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol 17: pp. 483-492
    16. Terakura, S, Murata, M, Nishida, T, Emi, N, Akatsuka, Y, Riddell, SR (2005) A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol 129: pp. 221-228
    17. Terakura, S, Murata, M, Nishida, T, Emi, N, Akatsuka, Y, Morishima, Y (2006) Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant 37: pp. 381-386
    18. Shamim, Z, Ryder, LP, Heilmann, C, Madsen, H, Lauersen, H, Andersen, PK (2006) Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant 37: pp. 485-491
    19. Keen, LJ, DeFor, TE, Bidwell, JL, Davies, SM, Bradley, BA, Hows, JM (2004) Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 103: pp. 3599-3602
    20. MacMillan, ML, Radloff, GA, Kiffmeyer, WR, DeFor, TE, Weisdorf, DJ, Davies, SM (2003) High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation 76: pp. 1758-1762
    21. MacMillan, ML, Radloff, GA, DeFor, TE, Weisdorf, DJ, Davies, SM (2003) Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 121: pp. 597-604
    22. Mehta, PA, Eapen, M, Klein, JP, Gandham, S, Elliott, J, Zamzow, T (2007) Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. Br J Haematol 137: pp. 152-157
    23. Sengsayadeth, S, Wang, T, Lee, SJ, Haagenson, MD, Spellman, S, Fernandez Vina, MA (2014) Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20: pp. 900-903
    24. Jagasia, M, Clark, WB, Brown-Gentry, KD, Crawford, DC, Fan, KH, Chen, H (2012) Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18: pp. 1069-1075
    25. Kim, M, Kim, J, Kim, JR, Han, E, Park, J, Lim, J (2014) FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1. Mol Biol Rep.
    26. Carvalho, A, Cunha, C, Ianni, M, Pitzurra, L, Aloisi, T, Falzetti, F (2010) Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant 45: pp. 1645-1652
    27. Ambruzova, Z, Mrazek, F, Raida, L, Jindra, P, Vidan-Jeras, B, Faber, E (2009) Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 44: pp. 227-235
    28. Tseng, LH, Storer, B, Petersdorf, E, Lin, MT, Chien, JW, Grogan, BM (2009) IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation 87: pp. 704-710
    29. Elmaagacli, AH, Steckel, N, Ditschkowski, M, Hegerfeldt, Y, Ottinger, H, Trenschel, R (2011) Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors. Bone Marrow Transplant 46: pp. 702-708
    30. McDermott, DH, Conway, SE, Wang, T, Ricklefs, SM, Agovi, MA, Porcella, SF (2010) Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood 115: pp. 2311-2318
    31. Takami, A, Espinoza, JL, Onizuka, M, Ishiyama, K, Kawase, T, Kanda, Y (2011) A single-nucleotide polymorphism of the Fcgamma receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. Bone Marrow Transplant 46: pp. 238-243
    32. Vannucchi, AM, Guidi, S, Guglielmelli, P, Glinz, S, Lombardini, L, Busca, A (2007) Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. Bone Marrow Transplant 40: pp. 1001-1002
    33. Perez-Garcia, A, Camara, R, Roman-Gomez, J, Jimenez-Velasco, A, Encuentra, M, Nieto, JB (2007) CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 110: pp. 461-467
    34. Wu, J, Tang, JL, Wu, SJ, Lio, HY, Yang, YC (2009) Functional polymorphism of CTLA-4 and ICOS genes in allogeneic hematopoietic stem cell transplantation. Clin Chim Acta Int J Clin Chem 403: pp. 229-233
    35. Metaxas, Y, Bertz, H, Spyridonidis, A, Spyroupoulou-Vlachou, M, Porzelius, C, Finke, J (2012) CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia. Bone Marrow Transplant 47: pp. 411-415
    36. Hauser, H, Zach, O, Krieger, O, Kasparu, H, Koenig, J, Girschikofsky, M (2008) A single nucleotide polymorphism at chromosome 2q21.3 (LCT -13910C>T) associates with clinical outcome after allogeneic hematopoietic stem cell transplantation. Blood 112: pp. 2156-2159
    37. Kim, DD, Yun, J, Won, HH, Cheng, L, Su, J, Xu, W (2012) Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease. Transplantation 94: pp. 1250-1257
    38. Straaten, HM, Paquay, MM, Tilanus, MG, Geloven, N, Verdonck, LF, Huisman, C (2011) NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 17: pp. 1231-1236
    39. Madrigal, A, Shaw, BE (2008) Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. Blood Cells Mol Dis 40: pp. 40-43
    40. Granell, M, Urbano-Ispizua, A, Arostegui, JI, Fernandez-Aviles, F, Martinez, C, Rovira, M (2006) Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica 91: pp. 1372-1376
    41. Holler, E, Rogler, G, Brenmoehl, J, Hahn, J, Herfarth, H, Greinix, H (2006) Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107: pp. 4189-4193
    42. Holler, E, Rogler, G, Herfarth, H, Brenmoehl, J, Wild, PJ, Hahn, J (2004) Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104: pp. 889-894
    43. Holler, E, Hahn, J, Andreesen, R, Rogler, G, Brenmoehl, J, Greinix, H (2008) NOD2/CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters. J Clin Oncol Off J Am Soc Clin Oncol 26: pp. 338-339
    44. Mayor, NP, Shaw, BE, Hughes, DA, Maldonado-Torres, H, Madrigal, JA, Keshav, S (2007) Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol Off J Am Soc Clin Oncol 25: pp. 4262-4269
    45. Nguyen, Y, Al-Lehibi, A, Gorbe, E, Li, E, Haagenson, M, Wang, T (2010) Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. Blood 115: pp. 3625-3631
    46. Sairafi, D, Uzunel, M, Remberger, M, Ringden, O, Mattsson, J (2008) No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant 41: pp. 961-964
    47. Mayor, NP, Shaw, BE, Madrigal, JA, Marsh, SG (2008) No impact of NOD2/CARD15 on outcome after SCT: a reply. Bone Marrow Transplant 42: pp. 837-838
    48. Velden, WJ, Blijlevens, NM, Maas, FM, Schaap, NP, Jansen, JH, Reijden, BA (2009) NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplant 44: pp. 243-248
    49. Holler, E, Rogler, G, Brenmoehl, J, Hahn, J, Greinix, H, Dickinson, AM (2008) The role of genetic variants of NOD2/CARD15, a receptor of the innate immune system, in GvHD and complications following related and unrelated donor haematopoietic stem cell transplantation. Int J Immunogenet 35: pp. 381-384
    50. Cho, HJ, Shin, DY, Kim, JH, Bae, JY, Lee, KH, See, CJ (2012) Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantation. Clin Transpl 26: pp. 476-483
    51. Dickinson, AM, Pearce, KF, Norden, J, O'Brien, SG, Holler, E, Bickeboller, H (2010) Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica 95: pp. 922-927
    52. Bogunia-Kubik, K, Middleton, P, Norden, J, Dickinson, A, Lange, A (2008) Association of vitamin D receptor polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Int J Immunogenet 35: pp. 207-213
    53. Middleton, PG, Cullup, H, Dickinson, AM, Norden, J, Jackson, GH, Taylor, PR (2002) Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 30: pp. 223-228
    54. Rocha, V, Porcher, R, Fernandes, JF, Filion, A, Bittencourt, H, Silva, W (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23: pp. 545-556
    55. Kim, I, Lee, KH, Kim, JH, Ra, EK, Yoon, SS, Hong, YC (2007) Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann Hematol 86: pp. 41-48
    56. Rachakonda, SP, Penack, O, Dietrich, S, Blau, O, Blau, IW, Radujkovic, A (2014) Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol Off J Am Soc Clin Oncol 32: pp. 3421-3427
    57. Dickinson, AM, Middleton, PG, Rocha, V, Gluckman, E, Holler, E, Eurobank, M (2004) Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol 127: pp. 479-490
    58. Mayor, NP, Shaw, BE, Madrigal, JA, Marsh, SG (2012) NOD2 polymorphisms and their impact on haematopoietic stem cell transplant outcome. Bone Marrow Res 2012: pp. 180391
    59. Elmaagacli, AH, Koldehoff, M, Steckel, NK, Trenschel, R, Ottinger, H, Beelen, DW (2007) Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 40: pp. 659-664
    60. Kreyenberg, H, Jarisch, A, Bayer, C, Schuster, B, Willasch, A, Strahm, B (2011) NOD2/CARD15 gene polymorphisms affect outcome in pediatric allogeneic stem cell transplantation. Blood 118: pp. 1181-1184
    61. Hugot, JP, Zaccaria, I, Cavanaugh, J, Yang, H, Vermeire, S, Lappalainen, M (2007) Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 102: pp. 1259-1267
    62. Kugathasan, S, Loizides, A, Babusukumar, U, McGuire, E, Wang, T, Hooper, P (2005) Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn's disease. Inflamm Bowel Dis 11: pp. 631-638
    63. Khoury, MJ, Coates, RJ, Fennell, ML, Glasgow, RE, Scheuner, MT, Schully, SD (2012) Multilevel research and the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr 2012: pp. 112-120
    64. Ciurea, SO, Andersson, BS (2009) Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15: pp. 523-536
    65. Hassan, M, Andersson, BS (2013) Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 14: pp. 75-87
    66. Ekhart, C, Rodenhuis, S, Smits, PH, Beijnen, JH, Huitema, AD (2008) Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 18: pp. 1009-1015
    67. Ekhart, C, Doodeman, VD, Rodenhuis, S, Smits, PH, Beijnen, JH, Huitema, AD (2008) Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 18: pp. 515-523
    68. Daly, AK (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17: pp. 27-41
    69. Kropp, S, Lichtinghagen, R, Winterstein, K, Schlimme, J, Schneider, U (2006) Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry. Clin Lab 52: pp. 237-240
    70. Melanson, SE, Stevenson, K, Kim, H, Antin, JH, Court, MH, Ho, VT (2010) Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol 85: pp. 967-971
    71. Slattery, JT, Risler, LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20: pp. 543-549
    72. Johnson, L, Orchard, PJ, Baker, KS, Brundage, R, Cao, Q, Wang, X (2008) Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 48: pp. 1052-1062
    73. Bonifazi, F, Storci, G, Bandini, G, Marasco, E, Dan, E, Zani, E (2014) Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. Haematologica 99: pp. 172-179
    74. Hahn, T, Zhelnova, E, Sucheston, L, Demidova, I, Savchenko, V, Battiwalla, M (2010) A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 16: pp. 801-808
    75. Muller, P, Asher, N, Heled, M, Cohen, SB, Risch, A, Rund, D (2008) Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 32: pp. 919-929
    76. Wang, F, Liang, YJ, Wu, XP, Chen, LM, To, KK, Dai, CL (2011) Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. Eur J Cancer 47: pp. 1990-1999
    77. Pinto, N, Ludeman, SM, Dolan, ME (2009) Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10: pp. 1897-1903
    78. Chien, JW, Zhang, XC, Fan, W, Wang, H, Zhao, LP, Martin, PJ (2012) Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood 119: pp. 5311-5319
    79. Mullally, A, Ritz, J (2007) Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 109: pp. 1355-1362
    80. Gumperz, JE, Barber, LD, Valiante, NM, Percival, L, Phillips, JH, Lanier, LL (1997) Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol 158: pp. 5237-5241
    81. Giebel, S, Locatelli, F, Lamparelli, T, Velardi, A, Davies, S, Frumento, G (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102: pp. 814-819
    82. Ruggeri, L, Capanni, M, Urbani, E, Perruccio, K, Shlomchik, WD, Tosti, A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: pp. 2097-2100
    83. Davies, SM, Ruggieri, L, DeFor, T, Wagner, JE, Weisdorf, DJ, Miller, JS (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100: pp. 3825-3827
    84. Bari, R, Rujkijyanont, P, Sullivan, E, Kang, G, Turner, V, Gan, K (2013) Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol 31: pp. 3782-3790
    85. Cooley, S, Weisdorf, DJ, Guethlein, LA, Klein, JP, Wang, T, Marsh, SG (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192: pp. 4592-4600
    86. Weisdorf, D, Cooley, S, Devine, S, Fehniger, TA, DiPersio, J, Anasetti, C (2012) T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18: pp. 937-943
    87. Cooley, S, Weisdorf, DJ, Guethlein, LA, Klein, JP, Wang, T, Le, CT (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116: pp. 2411-2419
    88. Cooley, S, Trachtenberg, E, Bergemann, TL, Saeteurn, K, Klein, J, Le, CT (2009) Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113: pp. 726-732
    89. Venstrom, JM, Pittari, G, Gooley, TA, Chewning, JH, Spellman, S, Haagenson, M (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367: pp. 805-816
    90. Uhrberg, M, Parham, P, Wernet, P (2002) Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 54: pp. 221-229
    91. Hsu, KC, Chida, S, Geraghty, DE, Dupont, B (2002) The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190: pp. 40-52
    92. Hsu, KC, Liu, XR, Selvakumar, A, Mickelson, E, O'Reilly, RJ, Dupont, B (2002) Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 169: pp. 5118-5129
    93. Venstrom, JM, Gooley, TA, Spellman, S, Pring, J, Malkki, M, Dupont, B (2010) Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 115: pp. 3162-3165
    94. Jia, X, Han, B, Onengut-Gumuscu, S, Chen, WM, Concannon, PJ, Rich, SS (2013) Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 8: pp. e64683
    95. Leslie, S, Donnelly, P, McVean, G (2008) A statistical method for predicting classical HLA alleles from SNP data. Am J Hum Genet 82: pp. 48-56
    96. Dilthey, A, Leslie, S, Moutsianas, L, Shen, J, Cox, C, Nelson, MR (2013) Multi-population classical HLA type imputation. PLoS Comput Biol 9: pp. e1002877
    97. Pillai, NE, Okada, Y, Saw, WY, Ong, RT, Wang, X, Tantoso, E (2014) Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum Mol Genet 23: pp. 4443-4451
    98. Dignam, JJ, Kocherginsky, MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol Off J Am Soc Clin Oncol 26: pp. 4027-4034
    99. Fine, JP, Gray, RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: pp. 496-509
    100. Logan, BR, Zhang, MJ, Klein, JP (2006) Regression models for hazard rates versus cumulative incidence probabilities in hematopoietic cell transplantation data. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 12: pp. 107-112
    101. Klein, JP (2006) Modelling competing risks in cancer studies. Stat Med 25: pp. 1015-1034
    102. Latouche, A, Allignol, A, Beyersmann, J, Labopin, M, Fine, JP (2013) A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol 66: pp. 648-653
  • 刊物主题：Hematology; Oncology; Geriatrics/Gerontology;
  • 出版者：Springer US
  • ISSN：1558-822X
文摘
Overall survival following hematopoietic cell transplantation (HCT) has improved over the past two decades through better patient selection and advances in HLA typing, supportive care, and infection prophylaxis. Nonetheless, mortality rates are still unsatisfactory and transplant-related mortality remains a major cause of death after unrelated allogeneic HCT. Since there are no known pre-HCT, non-HLA biologic predictors of survival following transplant, for over a decade, scientists have been investigating the role of non-HLA germline genetic variation in survival and treatment-related mortality after HCT. Variation in single nucleotide polymorphisms (SNPs) has the potential to impact chemotherapy, radiation, and immune responses, leading to different post-HCT survival outcomes. In this paper, we address the current knowledge of the contribution of genetic variation to survival following HCT and discuss study design and methodology for investigating HCT survival on a genomic scale.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700